(CercleFinance.com) – Sanofi announces the results of the RILECSU phase II study showing that its rilzabrutinib can quickly reduce the severity of itching caused by chronic spontaneous urticaria and significantly improve the activity of the disease in the adult.
These results were presented on Saturday in the form of a poster at the 2024 Congress of the American Academy of Allergy, Asthma and Immunology (AAAAI) which is being held in Washington, and form the basis of the phase III program which should begin in 2024.
‘Results from pivotal phase III trials in the treatment of immune thrombocytopenia and phase II in asthma, IgG4 disease and autoimmune hemolytic anemia are expected in 2024’, adds the healthcare giant .